Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial † † Data from this study were presented in part at the 2013 Genitourinary Cancer Symposium, Orlando, FL, February 14–16.
Titel:
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial † † Data from this study were presented in part at the 2013 Genitourinary Cancer Symposium, Orlando, FL, February 14–16.
Auteur:
Procopio, G. Verzoni, E. Bracarda, S. Ricci, S. Sacco, C. Ridolfi, L. Porta, C. Miceli, R. Zilembo, N. Bajetta, E.